Entities Foreign Institutions are not eligible to apply. Non-domestic non-U. Organizations are not eligible to apply. All registrations must be completed prior to the application being submitted.
|Published (Last):||2 November 2013|
|PDF File Size:||10.95 Mb|
|ePub File Size:||9.58 Mb|
|Price:||Free* [*Free Regsitration Required]|
Entities Foreign Institutions are eligible to apply. Non-domestic non-U. Organizations are eligible to apply. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission. The same DUNS number must be used for all registrations, as well as on the grant application.
The renewal process may require as much time as the initial registration. Obtaining an eRA Commons account can take up to 2 weeks. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for FDA support.
Additional Information on Eligibility Number of Applications Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time. This means that the FDA will not accept: A new A0 application that is submitted before issuance of the summary statement from the review of an overlapping new A0 or resubmission A1 application.
A resubmission A1 application that is submitted before issuance of the summary statement from the review of the previous new A0 application. Section IV. Application and Submission Information 1. See your administrative office for instructions if you plan to use an institutional system-to-system solution. Conformance to the requirements in the Application Guide is required and strictly enforced.
Applications that are out of compliance with these instructions may be delayed or not accepted for review. Letter of Intent Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows FDA staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Malhotra fda. The conference call information will be provided to prospective applicants that submit a letter of intent. The technical session will provide an overview of the submission requirements and allow prospective applicants an opportunity to ask questions regarding the application process.
Participation in the technical session is optional, but strongly encouraged. A portion of the budget should be reserved for travel to participate in site visits or attend meetings as requested by the FDA. Appendix: Do not use the Appendix to circumvent page limits. FOAs that do not allow clinical trials use this form for human subjects.
Foreign Institutions Foreign non-U. Section III. Submission Dates and Times Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications to Grants. Late applications will not be accepted for this FOA. Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission. Intergovernmental Review E. Additional funding restrictions may be part of the Notice of Award. Paper applications will not be accepted. Applicants must complete all required registrations before the application due date.
Eligibility Information contains information about registration. For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the assigned Grants Management Specialist and responsiveness by components of participating organizations , FDA. Section V. Application Review Information 1. Criteria Only the review criteria described below will be considered in the review process. Scored Review Criteria Reviewers will consider each of the review criteria below in the determination of scientific merit.
Significance 20 Points Does the project address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field s?
Innovation 20 Points Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense?
Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? Approach 20 Points Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project?
Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented?
If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
Environment 20 Points Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed?
Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
Additional Review Criteria As applicable for the project proposed, reviewers will evaluate the following additional items, but will not give separate scores for these items and should not consider them in providing an overall score.
Vertebrate Animals The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: 1 description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; 2 justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; 3 interventions to minimize discomfort, distress, pain and injury; and 4 justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals.
Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
AFNOR Editions Online Store
January Number of pages: Aggregates — Criteria for qualification natural aggregates for hydraulic concrete with respect to the alkali-reaction — Granulats. Affiliation List of ICS codes. We make no representation or warranty as to which of the Indices will be cd Lesser Performing Index for the purposes of calculating your return on the notes at maturity. May Number of pages: Even if there is a secondary market, p may not provide enough liquidity to allow you to trade or sell the notes easily. You may access these documents on the SEC website at www.
AFNOR FD P18-011
You should consider carefully whether the notes are suitable to your investment goals. No additional registration fee has been paid with respect to this offering. Testing fresh concrete — Part 5: Register dd at inter and intra-company training, and certifying diplomas, seminars, distance learning. No statutory, judicial or administrative authority directly addresses the treatment of the notes or instruments similar to the notes for U. Legal notices Photo credits FAQ. You should read this pricing supplement together with the prospectus dated December 1,as supplemented by the prospectus supplement dated October 12, relating to our Series E medium-term notes of which these notes are a part, and the more detailed information contained in product supplement no. Fidelity of test methods.
FD P18-011 PDF
Akilkis Destruel Date of publication: Terms and conditions for Customized compilation of standards Contact us Accessibility. Discover also Certification, assessment, diagnosis Get a quote for certification of systems, products or services, and get certified. You may access these documents on the SEC website at www. Aggregates — defining elements, conformity and coding — Granulats.